bioAffinity Technologies (BIAF) Share-based Compensation (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Share-based Compensation for 6 consecutive years, with $13266.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 95.94% year-over-year to $13266.0; the TTM figure through Mar 2026 stood at $617608.0 (down 40.25% YoY), while the FY2025 annual figure was $671474.0, down 32.15% from the prior year.
• Share-based Compensation declined to $13266.0 in Q1 2026 per BIAF's latest filing, from $66119.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $326616.0 in Q1 2025 and bottomed at $13266.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $162794.0 across 5 years, with a median of $177971.0 in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation soared 538.02% — and 2026, when it slumped 95.94%.
• bioAffinity Technologies' Share-based Compensation stood at $36847.0 in 2022, then soared by 536.44% to $234510.0 in 2023, then fell by 0.18% to $234087.0 in 2024, then tumbled by 71.75% to $66119.0 in 2025, then sank by 79.94% to $13266.0 in 2026.
• Business Quant data shows BIAF's Share-based Compensation at $13266.0 in Q1 2026, $66119.0 in Q4 2025, and $211607.0 in Q2 2025.